A groundbreaking clinical trial is set to evaluate a novel drug combination aimed at providing enduring relief for individuals suffering from panic disorder, a debilitating condition known for disrupting everyday life and posing challenges for effective treatment. With no new medications approved for this condition since 2003, researchers at the Mackay Institute of Research and Innovation (MIRI) are focusing on recruiting participants aged 18-65 who have been diagnosed with recurrent panic attacks. This trial will assess the efficacy of an oral medication combining two existing drugs, offering a potential solution that can alleviate symptoms without the risk of addiction commonly associated with current treatments.
Panic disorder affects approximately 4.7% of the US adult population, causing individuals to experience unexpected and intense episodes of fear that can lead to avoidance behaviors, creating a sense of being trapped in a psychological prison. While panic attacks themselves may not be physically harmful, the associated symptoms such as chest pain, dizziness, and shortness of breath can trigger a state of hypervigilance, making it a consuming and distressing condition. Notably, panic disorder accounts for the highest number of medical visits among all anxiety disorders, underscoring the significant burden it places on individuals’ lives.
One of the challenges in managing panic disorder stems from the fact that these attacks can be symptomatic of various other conditions like generalized anxiety disorder, social phobia disorder, and major depressive disorder. Moreover, triggers for panic attacks are highly individualized and unpredictable, often leading individuals into cycles of shame that exacerbate the condition. While treatment options typically include psychotherapy and medication, many individuals do not respond well to conventional therapies like cognitive behavioral therapy or SSRIs, while benzodiazepines are limited in use due to their potential for dependence and habit formation.
In the upcoming trial, researchers will closely monitor both the tolerability and effectiveness of the new medication over a 15-week period, utilizing a combination of in-person visits, video consultations, and ongoing support from medical professionals. By leveraging the safety profile of the two medications already in use for physical health conditions, the trial aims to provide a safer and more sustainable treatment option for individuals with panic disorder. The research team, led by psychiatrists Alok Rana, M.D., and Graham Pasternak, is optimistic about the potential of this unnamed drug combination to bring about transformative changes in the lives of those struggling with this debilitating condition.
With a focus on mitigating the risk of tolerance, dependence, and addiction commonly associated with existing treatments, the new drug combination offers a ray of hope for individuals seeking long-term relief from panic disorder. By addressing the symptomatic relief without the drawbacks of traditional medications like Valium, which can lead to dependence and addiction, this novel approach holds promise for reducing the long-term functional decline often observed in mental illnesses. As the trial gears up to commence this year upon reaching recruitment targets, individuals interested in participating in this study based in Australia can reach out to the research team for more information.
- The upcoming clinical trial of a novel drug combination for panic disorder aims to provide a safe and effective long-term treatment option.
- By leveraging the safety profile of existing medications, researchers hope to address the limitations of current therapies and offer lasting relief to individuals with panic disorder.
- The trial will assess the tolerability and efficacy of the new medication over a 15-week period, with a focus on reducing the risk of dependence and addiction associated with traditional treatments.
- Psychiatrists leading the research team are optimistic about the potential of this drug combination to bring about positive changes in the lives of individuals grappling with the challenges of panic disorder.
Read more on newatlas.com